Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
Surrozen, Inc. (SRZN)
Company Research
Source: GlobeNewswire
Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413 is a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wingless/Integrated (Wnt) signaling, designed using Surrozen’s SWAP™ technology SZN-413 offers the possibility of restoring retinal function in patients living with retinal vascular diseases SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN) announced that Boehringer Ingelheim will further develop SZN-413 to advance the compound and prepare it for clinical testing. Surrozen is pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration. The milestone achievement triggers a $10 million payment to Surrozen as part of the agreement. Retinal vascular diseases are responsible for a large proportion of global severe and moderate vision loss affecting close to 150 million people.
Show less
Read more
Impact Snapshot
Event Time:
SRZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRZN alerts
High impacting Surrozen, Inc. news events
Weekly update
A roundup of the hottest topics
SRZN
News
- Surrozen to Present at Upcoming Healthcare Investor ConferencesGlobeNewswire
- Surrozen Provides Third Quarter 2024 Financial Results and Business UpdateGlobeNewswire
- Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-ß Antibodies for Idiopathic Pulmonary Fibrosis [Yahoo! Finance]Yahoo! Finance
- Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-ß Antibodies for Idiopathic Pulmonary FibrosisGlobeNewswire
- Surrozen earns $10M milestone payment through Boehringer collaboration [Seeking Alpha]Seeking Alpha
SRZN
Earnings
- 5/8/24 - Beat
SRZN
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/14/24 - Form SCHEDULE
- 11/14/24 - Form SC
- SRZN's page on the SEC website